Tirabrutinib

Name: Tirabrutinib in Primary central nervous system lymphoma: Access and distribution
Published: 2026-09-14T15:39:06-04:00

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Access and distribution

1 evidence topic · 1 source

Marketed access: Japan

“Tirabrutinib has been approved and is currently marketed in Japan for relapsed or refractory (R/R) PCNSL patients.” (opens the source at this quote in a new tab)